The Analysis of Osteoconducting Ability of Alpha-Tricalcium Phosphate-Based Bone Filler Powder

Abstract:

Titanium alloy(Ti-6Al-4V, Samsung techwin, Korea) rods with diameter of 2.5mm were used as the implant materials. Polymethyl methacrylate(PMMA) bone cements(CMW, USA) were used as bone cement and
-tricalcium phosphate(TCP)-based bone filler powder was used as osteoconductive additives. Hydroxyapatite(HA) was the desired end product after hydrolysis of the
-TCP-based bone filler powder mixed with the blood. In animal study using rabbits, we divided the group into A, B, C and D. Rabbits were sacrificed at 1, 3, 9 weeks after implantation and the affinity index and bone density were calculated. X-ray diffraction patterns of HA formed by hydrolysis of
-TCP-based bone filler powder showed higher and higher intensity in HA peak with increase of time period. There was more bone density increase in the group B and D containing
- TCP-based bone filler powder around implant site than in the group A and C(p<0.05). It is suggested that HA formed by hydrolysis of
-TCP-based bone filler powder will play some parts in enhancing osteconducting ability in clinical settings.

• Periodical: Key Engineering Materials (Volumes 309-311)
• Pages: 259-262
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.309-311.259
• Online since: May 2006
• Authors: Jeong Hyun Yoo, Kang Sik Lee, Soo Ho Lee
• Keywords: Alpha-Tricalcium Phosphate, Bone Cement, Bone Filler, Hydroxyapatite (HAP), Implant

References

[1] W.E. Brown and L.C. Chow: U.S. Patent No. 4518430, (1985).

[2] E. Fernandez, F.J. Gil, M.P. Ginebra, F.C.M. Driessens, J.A. Planell: J. Mater. Sci. Mater. Med. Vol. 10(1999), p.169.

[3] E. Fernandez, F.J. Gil, M.P. Ginebra, F.C.M. Driessens, J.A. Planell: J. Mater. Sci. Mater. Med. Vol. 10(1999), p.177.

[4] K. Ishikawa and K. Asaoka: Biomaterials, Vol. 16(1995), p.527.

[5] F.C.M. Driessens, M.G. Boltong, M.I. Zapatero, R.M.H. Verbeeck, W. Bonfield, O. Bernudez, E. Fernandez, M.P. Ginebra and J.A. Planell: J. Mater. Sci. Mater. Med. Vol. 6(1995), p.272.

DOI: 10.1007/bf00120270

[6] Oonishi H, Kadoya Y, Iwaki H, Kin N.: The Journal of Arthroplasty, Vol16(2001), p.784 (c) (d) (e) (b) (a).

[10] [20] [30] [40] [50] [60] [70] Group A Group B Group C Group D Affinity Index(%).

[1] week.

[3] weeks.

[9] weeks.

[40] [45] [50] [55] [60] [65] Group A Group B Group C Group D Bone density(%).

[1] week.

[3] weeks.

[9] weeks.